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Recurrent pregnancy loss is a frustrating clinical dilemma for both patients 
and physicians because, in most cases, causes are nebulous and few 
treatments with proven benefit can be offered. Involved, expensive tests 
have frequently been proposed and their use has often filtered into clinical 
practice before their u tility  has been firm ly demonstrated. Proposed causes 
of recurrent pregnancy loss include genetic and environmental etiologies, 
infectious agents, maternal congenital and acquired anatomic abnormalities, 
and immunologic and endocrinologic dysfunction. Appropriate management 
relies upon a realistic understanding of the often substantial limitations of 
currently available therapies.
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Introduction
Human reproduction is an inefficient process. Only ap­
proximately 20% o f  attempted conception cycles will 
result in clinical pregnancies. Furthermore, 50—75% o f  
conceptions will result in miscarriage. O f  women aspir­
ing to conceive, 25% will suffer at least one clinically 
recognized early pregnancy loss during their reproduc­
tive careers. Losses comprise 15-20% o f  all clinically ev­
ident pregnancies, and 0.5-1%  o f  women will meet the 
classical definition for recurrent pregnancy loss (RPL) 
by having three or more clinically recognized consec­
utive pregnancy losses. These women represent a pro­
portion w ho simply have sporadic bad luck three times 
in a row, as well as women who have underlying repro­
ductive problems predisposing to losses.
Proposed causes of recurrent pregnancy loss
After having a first miscarriage, couples inevitably ask 
why this happened. The most frequent known cause 
o f  sporadic spontaneous abortion (SAB) is cytogenetic 
abnormalities o f  the conceptus. Half o f  preimplantation 
embryos examined and one-third o f  embryos that have 
implanted are abnormal morphologically, which is most 
often the result o f  an underlying genetic defect.
Aside from genetic abnormalities, there are environ­
mental causes o f  sporadic early pregnancy loss which 
could theoretically be associated with RPL if  a preg­
nant woman was persistently exposed. Recently, chronic
exposure to video display terminals o f  more than 20 h 
each week has been proposed to be a cause o f  SAB. This 
claim has been refuted [1], Recent studies examining the 
association, if any, between caffeine intake and RPL have 
come to opposite conclusions [2,3],
Definitive roles for cigarette smoke, alcohol, anesthetic 
agents, heavy metals, chloroquine, oral hypoglycemics 
and industrial organic solvents as contributors to preg­
nancy loss remain conjectural. There is some epidemio­
logic evidence that smoking more than 14 cigarettes/day 
increases the risk o f  aborting a euploid conceptus 1.7 
times [4]. Likewise, moderate drinking during 2 days 
o f  the week may double the risk over nondrinkers o f  
euploid abortion [5],
Genetic
Embryonic aneuploidy is the only proposed etiology o f  
RPL for which there is general agreement. To have 
genetically induced RPL, couples must have abnormal 
genetic complements which are compatible with nor­
mal parental phenotypes and the ability to conceive, yet 
which persistently result in genetically abnormal concep- 
tuses that are unable to endure. These conditions can be 
fulfilled when at least one member o f  a couple has chro­
mosomal aberrations with either an abnormal number 
o f  chromosomes (numerical abnormalities) or rearrange­
ments o f  the genetic material within the chromosomes 
(structural abnormalities). Moreover, to maintain nor­
mal phenotypes, these individuals must maintain com ­
plete (balanced) complements o f  chromosomal material,
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or have only minimally unbalanced parental genomes. 
The production o f  unbalanced gametes during meio- 
sis as a result o f  the parental structural chromosomal 
abnormalities yields either duplication or deficiency o f  
chromosomal segments in the resulting conceptuses as 
the cause o f  repetitive abortions.
In a compilation o f  79 cytogenetic studies o f  couples 
with two or more SABs, karyotypes from a total o f  
8298 women and 7834 men were reviewed [6], At 
least one member o f  2.9% o f  the couples had a detectable 
chromosomal abnormality, which is about five-six times 
the prevalence in the general population. The female 
partners were twice as likely to have a chromosomal ab­
normality than their male counterparts. Among all de­
tectable chromosome abnormalities, 50% had balanced 
reciprocal translocations, 25% had Robertsonian trans­
locations and 12% had X-chromosome mosaicism; and 
inversions and sporadic abnormalities made up the re­
mainder (Fig. 1). Normally, only one in 700 phenotypi­
cally normal people will have a translocation. Data from 
an even larger database including 199 studies and over 
29 000 persons having two or more miscarriages, found 
similar distributions [7], Thus, parental chromosomal 
problems can predispose to RPL in three major ways, 
translocations, inversions and mosaicism, with transloca­
tions being the most likely.
Fig. 1. Approximate proportions of karyotypic abnormalities found 
in individual parents when couples have two or more pregnancy 
losses [6].
A distinction should be made between the sporadic ge­
netic causes o f  SAB and the causes o f  RPL attributed 
to parental chromosomal abnormalities. Genetic causes 
are easily the most com mon demonstrable source o f  
sporadic abortions. About 50% o f  first trimester SABs
have chromosomal abnormalities. The distribution o f  
cytogenetic abnormalities found in abortus tissue reveals 
that most are abnormalities o f  chromosome numbers 
(Fig. 2). Abortus specimens from RPL are expected to 
have a smaller proportion o f  chromosomal abnormalities 
than sporadic SABs because RPL abortuses are a select 
population mostly resulting from predisposing etiologies 
other than sporadic genetic causes. Even when abortus 
material from couples with RPL has karyotypic abnor­
malities, the abnormalities may be sporadic and do not 
necessarily imply an increased risk for future pregnan­
cies. Therefore, routine cytogenetic analysis o f  abortus 
material is not currently indicated. A  more fruitful ap­
proach is to evaluate parental karyotypes in couples with 
RPL. Unfortunately, there are no conclusive historical 
elements to ascertain whether a parent has a translocation 
or not, including having had a previous phenotypically 
normal child. Only karyotyping can make the diagnosis.
Fig. 2. Approximate distribution of cytogenetic abnormalities found 
in clinically recognized sporadic spontaneous abortions [8**].
* most common single chromosomal abnormality.
To date, only cytogenetic abnormalities have been de­
tected in the search for genetic causes o f  RPL. Highly 
sensitive molecular genetic techniques now available of­
fer the hope o f  uncovering subchromosomal genetic 
mutations as sources o f  RPL, as has been done in an­
imal models. Adding support for such single gene pos­
sibilities, is a report o f  couples with RPL and normal 
karyotypes, who nonetheless have a risk higher than 
couples without RPL o f  having offspring with chromo­
somal abnormalities [9]. A  novel example o f  a possible 
single gene defect has come to light based on case re­
ports. Evidence shows that faulty centromere function 
may prematurely allow centromere division. This could 
be associated with chromosome instability and cell divi­
sion errors as a source o f  RPL [10*]. Further support for 
the possibility o f  chromosome instability is provided by 
studies that have found methotrexate and other clasto-
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gens to have increased chromosomal breakage rates in 
lymphocytes from couples with RPL compared with 
control couples [11]. Currently there are no tests for sub- 
chromosomal genetic mechanisms that may cause RPL.
Infectious
For an infectious agent to cause repetitive pregnancy 
loss, it would have to be able to exist in a chronic 
state. Such infections are unusual in otherwise asymp­
tomatic women. The T  strain mycoplasmas ( Ureaplasma 
urealyticum and Mycoplasma hominis) have been proposed 
to cause RPL. However, mycoplasmas are highly preva­
lent in the cervices o f  normal women, and the results 
o f  antibiotic trials have been mixed. Also, there are still 
no studies with culture-proven mycoplasma in abortus 
material.
A  number o f  agents including viruses, bacteria, my­
coplasmas, and parasites (such as toxoplasma and Chlamy­
dia trachomatis) appear to be involved in sporadic losses 
and potentially severe pregnancy disorders, but their in­
volvement in RPL remains unproven. Definitive roles for 
the utility o f  cervical and endometrial cultures, serologi­
cal testing and alternatively, empiric antibiotic treatment 
for couples with RPL are lacking. These procedures 
should only be considered individually if there is clinical 
suspicion o f  an infectious agent precipitating recurrent 
losses.
Maternal anatomic abnormalities
Both congenital and acquired uterine abnormalities have 
been associated with RPL. Uterine anomalies have been 
reported to be present in up to 15% o f  couples with 
RPL. The scarcity o f  specific uterine abnormalities, 
the urgency to offer treatment when they are discov­
ered, and the ethical problem o f  not offering a treatment 
that may have benefit, have all slowed the determination 
o f  causality o f  RPL. We are left with trials o f  therapy 
which are largely uncontrolled, and therefore we cannot 
completely assess their attributable benefit. Nevertheless, 
it is highly probable that incompetent cervix is a cause 
o f  RPL. By definition, an incompetent cervix does not 
allow a pregnancy to reach term, and this implies per­
sistent risk with each pregnancy. Prevalence rates from 
<1%  all the way up to 15% have been observed for 
couples with RPL [12]. Most studies o f  treatment for 
incompetent cervix have used women who have already 
experienced morbidity from an episode o f  cervical in­
competence to serve as their own controls. This study 
design is vulnerable to selection bias. Nonetheless, a 
review o f  61 such studies suggests that the chance o f  
successful gestation in women with cervical incompe­
tence is approximately one in four before having a cer­
clage procedure, and about three in four after cerclage 
[12], Benefit from cerclage has not yet been confirmed 
in the few randomized, prospective studies conducted.
Among the numerous congenital uterine anomalies, 
septa have commonly been regarded as presenting the 
highest risk for miscarriage. However, a series o f  182 
women with uterine anomalies indicates that the unicor- 
nuate uterus is nearly twice as likely to be associated with 
SAB (approximately 50%) than septate and bicornuate 
uteri [13]. However, because septate uteri appear to be 
four or five times more common than unicornuate uteri, 
the septate uterus is probably the most likely Mullerian 
abnormality to be associated with pregnancy loss. There 
are few data to suggest how many SABs, if  any, should 
be tolerated before reducing a septum. Moreover, there 
is still no randomized study o f  expectant management 
compared with septum reduction.
Intrauterine adhesions
It seems plausible that intrauterine adhesions can cause 
RPL. The degree o f  intrauterine adhesions required to 
precipitate RPL is unknown, however, so making the 
decision o f  which women with RPL to treat is subjec­
tive. N o single best treatment protocol has surfaced, but 
March and Israel [14] observed an increased rate o f  preg­
nancy success from a baseline o f  16.7% to 87.2% after 
hysteroscopic lysis o f  adhesions using microscissors fol­
lowed by high-dose estrogen treatment for 2 months.
Leiomyomata uteri
As with intrauterine adhesions, a cause and effect rela­
tionship between leiomyomata and RPL is difficult to 
confirm. The impression that myomas may be involved 
in pregnancy loss again comes from nonrandomized 
studies which present SAB rates after myomectomy com ­
pared with the before therapy rates in select populations. 
Data assembled by Buttram and Reiter [15] from 1941 
such women reported in seven studies show a reduction 
in the SAB rate from 41% to 19% following myomec­
tomy. In practice, there are no reliable means o f  predict­
ing which clinical presentations are likely to respond 
to myomectomy. At this time, because o f  serious pos­
sible morbidity, myomectomy for the indication o f  RPL 
should only be considered when all other potential eti­
ologies have been excluded and suspicion is high that 
intracavitary distortion from leiomyomata are causative.
Diethylstilbestrol
Up to 1.5 million women carrying female fetuses are 
estimated to have taken diethylstilbestrol (DES) to bat­
tle against pregnancy loss until 1971 when the US Food 
and Drug Administration withdrew its approval. Inves­
tigations into the effect o f  DES on reproductive perfor­
mance indicate an increased likelihood (up to two times) 
o f  a DES-exposed daughter to miscarry [16]. However, 
data are too few to implicate DES as a certain cause for 
RPL. Moreover, the presence o f  cervical abnormalities 
and hysterosalpingographic abnormalities attributable to
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DES exposure do not predict SAB and cannot be used 
to dictate management [17]. Preconceptional cerclage 
to improve reproductive performance in DES-exposed 
women has not proven cost-effective. The number o f 
DES-exposed women o f  reproductive age is declining 
and the determination o f  their optimal management 
concerning RPL will probably not be possible.
The immune factor
Because pregnancies are immunologically privileged, re­
searchers have sought to confirm that a breach o f  this 
intricate and poorly understood phenomenon may lead 
to RPL. The bulk o f  recent research activity into the 
pathophysiology o f  RPL has focused on the immune 
factor. Two different categories o f  immune dysfunc­
tion have been scrutinized. Alloimmune refers to im­
munologic disparity between individuals o f  the same 
species, whereas autoimmune refers to immunologic ac­
tivity against one’s self.
Alloimmune
Although conceptually attractive, there are no definitive 
tests to prove that altered alloimmunity even exists as 
a cause o f  RPL. A  popular hypothesis has been that 
when partners share too many human leukocyte anti­
gens, which include the transplantation matching anti­
gens, proper maternal recognition o f  their conceptus 
may be thwarted such that immunological protection 
o f  the fetus cannot be afforded. However, studies look­
ing for human leukocyte antigen sharing among couples 
with RPL have found inconsistent associations. Fur­
thermore, none o f  the alloimmune immunologic tests 
such as the mixed lymphocyte reaction and antileuko- 
cytotoxic antibody testing have demonstrated predictive 
value for pregnancy outcome in couples with RPL [18], 
The tests are expensive, and presently have no practical 
value in the management o f  RPL.
Despite the lack o f  concrete methods to detect, predict 
or follow the presence o f  alloimmune RPL, empiric 
therapies have been attempted. The principal therapy 
for unexplained RPL, presumed to be o f  alloimmune 
origin, has been to immunize the women with partner 
or third-party leukocytes. The risk o f  transfusion reac­
tions, alloimmunization, infectious disease transmission 
and untoward fetal effects, implore the use o f  caution 
with this treatment. Until recently, there has been no 
standardization o f  admission criteria and immunization 
protocols, so efficacy has been difficult to assess. Meta­
analysis o f  four published, randomized, placebo-con­
trolled trials o f  immunotherapy by Fraser and colleagues 
[19**] involving 117 treated women and 129 control 
women demonstrates that there is fair evidence against its 
use. Another randomized placebo-controlled trial o f  im­
munotherapy for a selected group o f  women with RPL 
has since been published and found that therapy bor­
dered on but did not achieve a statistical benefit [20*].
An extensive meta-analysis is now being conducted by 
the American Society o f  Reproductive Immunology in­
cluding both published and unpublished data to further 
investigate the value o f  immunotherapy [21*]. Until fur­
ther elucidation o f  the safety and efficacy o f  immuno­
therapy, interested couples should be referred to research 
centers, and proper informed consent provided.
Autoimmune
Repetitive pregnancy loss is one presentation o f  the 
antiphospholipid syndrome (APS). Other clinical man­
ifestations may include venous or arterial thrombo­
sis as well as autoimmune thrombocytopenia. At least 
one elevation o f  an antiphospholipid antibody as well 
as a clinical manifestation confirms the diagnosis. 
The two pertinent antiphospholipid antibodies are lu­
pus anticoagulant (LAC) and anticardiolipin (ACL). 
Whereas ACL can be measured accurately by enzyme- 
linked immunoabsorbent assays using standards available 
from the Antiphospholipid Standardization Laboratory 
(Louisville, Kentucky), LAC requires more fastidious as­
says. The results o f  ACL testing are reported in the semi- 
quantitative terms ‘negative, low-positive, medium-posi­
tive, and high-positive’ . Only medium- or high-positive 
values are associated with APS.
W hen an automated activated partial thromboplastin 
time (APTT) prolongation is used to detect the pres­
ence o f  LAC, the assay must be depleted o f  proco­
agulant phospholipids for precision. A sample with an 
APTT prolongation should be mixed in a 1 :1 ratio 
with normal serum and retested. If the problem is a 
clotting factor deficiency rather than the presence o f  
LAC, then the APTT will correct. Finally, to confirm 
that LAC is the cause o f  a prolonged APTT, the addi­
tion o f  excess phospholipid to the assay should correct 
the APTT. Antinuclear antibody titers and other autoan­
tibody titers do not consistently predict miscarriage. At 
this time, among the autoantibodies, only LAC and ACL 
should be obtained during the evaluation o f  RPL.
Autoimmunity may play a role in up to 5-10%  o f  
women with RPL. While the pathophysiology is un­
clear, decidual vasculopathy and placental thrombosis 
are com mon observations in women suspected o f  au­
toimmune RPL. An intriguing line o f  investigation has 
demonstrated (in a murine model o f  APS with RPL), 
that interleukin-3 serum concentrations are diminished. 
The addition o f  exogenous interleukin-3 to these mice 
appears to avert ischemic placental atrophy and almost 
completely prevents RPL [22*].
The selective use o f  cytokines may one day prove to 
be the most effective treatment for APS in humans. 
In the meantime, treatment o f  APS-mediated RPL has 
been attempted with various combinations o f  heparin, 
low-dose aspirin (81 mg/day), glucocorticoids, and in­
travenous immunoglobulins. To date, the lack o f  appro­
priate controls and the inconsistent inclusion criteria and 
treatment protocols has made a treatment consensus im­
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possible. In has been assumed that it is rare for a woman 
with APS and RPL to reproduce successfully without 
treatment. Various treatment protocols report successful 
pregnancies 55-85%  o f  the time. Prednisone and low- 
dose aspirin, and heparin with or without aspirin have 
been popular regimens. A critical consideration is that 
women with APS and their fetuses remain at high risk 
for complications despite treatment. Branch et al. [23] 
found that one-half o f  treated women with APS devel­
oped pre-eclampsia and one-half suffered fetal distress, 
while over one-third delivered prematurely and another 
one-third had small-for-gestational-age infants. Five per­
cent o f  the cohort also developed thrombosis which in­
cluded a stroke. One treatment combination that may 
be particularly hazardous is a combination o f  heparin 
and glucocorticoids due to the potential additive risk o f  
osteoporosis [24*]. _
Endocrine factors
Poorly controlled systemic endocrinopathies, such as 
diabetes and thyroid dysfunction, can probably cause 
pregnancy loss. However, because severe manifestations 
o f  these disorders are found infrequently in populations 
o f  women with RPL and are clinically obvious, their 
overall contribution to RPL is negligible. As there is no 
evidence that asymptomatic endocrine problems lead to 
RPL, testing serum thyroid, glucose and prolactin con­
centrations is unproductive.
Luteal phase inadequacy (LPI) refers to an endometrium 
that is physiologically incapable o f  allowing normal im­
plantation or pregnancy maintenance, and has been re­
ported to be present in as many as 40% o f  cases o f  RPL. 
Diagnosis is perplexing because neither serum proges­
terone concentrations or late luteal phase endometrial 
biopsies are diagnostically sensitive or specific. Up to 
3-4% o f  fertile controls will have false-positive diag­
noses o f  LPI by the standard endometrial biopsy criteria 
o f  late luteal phase biopsies out o f  phase by at least 2 days 
in two separate cycles. Because LPI is sometimes diag­
nosed by endometrial biopsy while concomitant serum 
progesterone concentrations are normal, and because a 
myriad o f  other factors beside progesterone deficiency 
may contribute to an inadequate endometrium, the en­
dometrial biopsy remains the gold standard test [25].
At this time there are no randomized controlled trials 
which have indicated a benefit from progesterone treat­
ment for LPI. Balasch et al. [26] in a small, non-ran- 
domized, non-placebo-controlled trial, found a statis­
tically significant advantage o f  progesterone supposito­
ries over no treatment for RPL with LPI. Progesterone 
is usually given as 25 mg suppositories twice daily be­
ginning on the third day after ovulation. If progesterone 
supplementation is considered, it should only be used in 
women with RPL who have demonstrated two out-of­
phase endometrial biopsies, with the understanding that 
it is still considered empiric therapy.
Counseling
Several generalizations are pertinent when counseling 
couples with RPL. First, the older the woman, the 
higher the risk o f  even chromosomally normal losses. 
Second, the later in gestation that previous losses occur, 
the greater the risk for future pregnancy loss. Third, the 
outcomes o f  previous pregnancies influence the risk o f  
future miscarriage. A  previous live birth confers a better 
prognosis than when all previous pregnancies have been 
losses. Fourth, early ultrasonographic confirmation o f  fe­
tal heart activity is not as reliable in predicting successful 
outcomes for couples with RPL compared with cou­
ples without a history o f  repetitive losses. Recent reports 
find that in women with RPL, early ultrasound detec­
tion o f  fetal heart activity is associated with only about 
an 80%) chance o f  a live-born whereas ordinarily a live 
embryo noted by first trimester ultrasonography is asso­
ciated with a >96%  rate o f  a live birth [27,28*]. Fifth, 
a recent report finds that a history o f  oligomenorrhea 
may predict a higher risk for miscarriage [29*]. This 
adds credibility to the claims that elevated preconcep- 
tional follicular phase luteinizing hormone serum con­
centrations may signal a higher risk o f  miscarriage, be­
cause oligomenorrheic women commonly have higher 
circulating luteinizing hormone concentrations. H ow­
ever, Quenby and Farquharson [29*] could not confirm 
that higher luteinizing hormone profiles correspond to 
RPL, and the point remains controversial. Sixth, it ap­
pears that the more pregnancy losses a couple have, the 
higher their chance may be o f  birth defects in future live- 
born children [30*]. This adds to the dispiriting evidence 
that couples with RPL may also have increased risks for 
infertility, prematurity and small-for-gestational-age in­
fants [31]. Even when the prognosis is not good, couples 
will find the information provided by their physicians 
helpful in guiding their future decision-making.
Evaluation and management
A thorough history should include a detailed obstetri­
cal summary, noting the gestational ages o f  pregnancy 
losses and interspersed live births. Family genetic and 
miscarriage histories are important as well as a com ­
plete history o f  environmental exposures. The possibility 
o f  APS should also be explored. Depending on the indi­
vidual clinical situation, it is not unreasonable to begin an 
evaluation following two consecutive SABs. A  judicious 
evaluation is outlined in Table 1. Still, the cost o f  a ‘com ­
plete’ workup may be over US$ 2000, and the chance o f  
finding an abnormality is reported to be less than 50% 
in some series.
When RPL is unexplained, frustration may tempt care­
takers to offer some form o f  treatment. Unfortunately, 
treatments for most suspected etiologies o f  RPL have not 
been validated with scientific rigor, so optimal manage­
ment includes resisting the urge to offer treatments that
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Table 1. A suggested evaluation for recurrent pregnancy loss.
History
1) Obtain a precise obstetric history noting documentation of
gestational ages and patterns of pregnancy losses.
2) Search for historical evidence of antiphospholipid syndrome
such as arterial or venous thromboses and thrombocytopenia.
3) Scrutinize family histories for patterns of RPL, and investigate
consanguinity among family members.
4) Ascertain potential adverse environmental exposures.
5) Inquire about possible gynecologic and obstetrical infections.
Physical examination
1) Perform a general physical examination noting in particular signs
of autoimmune dysfunction and advanced endocrinopathy.
2) During the pelvic examination, look for evidence of Mullerian
abnormalities and diethylstilbestrol exposure.
Testing
1) Hysterosalpingogram or hysteroscopy.
2) Late luteal phase endometrial biopsy (repeat in a subsequent
cycle if out of phase).
3) Karyotyping for both partners.
4) Lupus anticoagulant and anticardiolipin antibodies.
5) Other tests if indicated by history and physical examination.
may carry undue risks. It is wise to factor in the strength 
o f  association o f  a presumed cause o f  a couple’s RPL 
before recommending an empiric treatment. Couples 
with RPL need compassionate counseling. The fact that 
couples with even three consecutive unexplained losses 
have a reasonable chance o f  having a live-born child on a 
subsequent attempt, 50-75%, despite the lack o f  specific 
treatment, can be quite comforting. Several uncontrolled 
studies indicate that emotional support and counseling 
alone may favor successful outcomes [29*].
Conclusion
Systematic evaluation will identify a cause for RPL ap­
proximately half the time. Many treatments in current 
use for specific causes o f  RPL have been incompletely 
validated, and therefore require judgement and cau­
tion before implementation. W hen a cause for RPL 
cannot be determined, complex, expensive testing for 
possible alloimmune causes has not been useful. Like­
wise, the value o f  empiric immunotherapy still awaits 
confirmation and should be relegated to research centers. 
Attention to previous menstrual and reproductive histo­
ries adds invaluable information for counseling couples 
with RPL. A  realistic appraisal o f  unexplained RPL cur­
rently favors conservative management based on accurate 
counseling combined with the unlimited availability o f  
emotional support.
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